Brugada Syndrome
- PMID: 35331438
- DOI: 10.1016/j.jacep.2021.12.001
Brugada Syndrome
Abstract
Brugada syndrome (BrS) is an "inherited" condition characterized by predisposition to syncope and cardiac arrest, predominantly during sleep. The prevalence is ∼1:2,000, and is more commonly diagnosed in young to middle-aged males, although patient sex does not appear to impact prognosis. Despite the perception of BrS being an inherited arrhythmia syndrome, most cases are not associated with a single causative gene variant. Electrocardiogram (ECG) findings support variable extent of depolarization and repolarization changes, with coved ST-segment elevation ≥2 mm and a negative T-wave in the right precordial leads. These ECG changes are often intermittent, and may be provoked by fever or sodium channel blocker challenge. Growing evidence from cardiac imaging, epicardial ablation, and pathology studies suggests the presence of an epicardial arrhythmic substrate within the right ventricular outflow tract. Risk stratification aims to identify those who are at increased risk of sudden cardiac death, with well-established factors being the presence of spontaneous ECG changes and a history of cardiac arrest or cardiogenic syncope. Current management involves conservative measures in asymptomatic patients, including fever management and drug avoidance. Symptomatic patients typically undergo implantable cardioverter defibrillator insertion, with quinidine and epicardial ablation used for patients with recurrent arrhythmia. This review summarizes our current understanding of BrS and provides clinicians with a practical approach to diagnosis and management.
Keywords: Brugada syndrome; serious arrhythmic events; sudden cardiac death; ventricular fibrillation.
Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures The study was supported by the Heart in Rhythm Organization (Dr Krahn, Principal Investigator) that receives support from the Canadian Institute of Health Research (RN380020–406814). Dr Krahn has received support from the Sauder Family and Heart and Stroke Foundation Chair in Cardiology (Vancouver, Canada), the Paul Brunes Chair in Heart Rhythm Disorders (Vancouver, Canada), and the Paul Albrechtson Foundation (Winnipeg, Canada). Dr Behr has received funds from the Robert Lancaster Memorial Fund; and has undertaken consulting for Boston Scientific. Dr Hamilton is funded by a Canadian Institutes of Health Research grant, a Waugh Family Innovation grant from the Labatt Family Heart Centre (2019-2021), a Freeman Innovation Award from the Heart and Stroke Richard Lewar Centre of Excellence (2019), the Caitlyn Elizabeth Morris Memorial Foundation, the Alex Corrance Memorial Foundation, and Meredith Cartwright L.L.B. Dr Laksman is a consultant for Abbott, Medtronic, and Boston Scientific; and has received support from The University of British Columbia, Department of Medicine and the School of Biomedical Engineering, and The University of British Columbia Cardiology Academic Practice Plan. Dr Han is supported by a Robert and Elizabeth Albert Travel Grant from the RACP Foundation, Australia. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical